MeSH D015451 - b-cell chronic lymphocytic leukemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Ifosfamide, Mesna | Ifosfamide/mesna |  | 2002-02-26 |  |  |
| Cyclophosphamide | Neosar |  | 1993-04-29 |  |  | |
| Ingenus | Cyclophosphamide | Cyclophosphamide | 2036-02-15 | 2020-07-30 |  |  |
| Mylan | Cladribine | Cladribine |  | 2011-10-06 |  |  |
| Fludarabine | Fludarabine |  | 2011-12-21 |  |  | |
| Ifosfamide | Ifosfamide |  | 2012-11-26 |  |  | |
| Rising Pharmaceuticals | Fludarabine | Fludarabine |  | 2012-10-16 |  |  |
| Johnson & Johnson | Ibrutinib | Imbruvica |  | 2014-10-21 | $3,265 M | Y2023 |
| Cladribine | Leustatin |  | 1993-02-26 |  |  | |
| Roche | Obinutuzumab | Gazyvaro |  | 2014-07-22 |  |  |
| Rituximab | MabThera |  | 1998-06-02 |  |  | |
| Cipla | Cyclophosphamide | Cyclophosphamide |  | 2019-01-18 |  |  |
| Sandoz | Fludarabine | Fludarabine |  | 2007-09-21 |  |  |
| Rituximab | Rixathon |  | 2017-06-15 |  |  | |
| Cyclophosphamide | Cyclophosphamide |  | 2023-09-12 |  |  | |
| AbbVie | Venetoclax | Venclyxto |  | 2016-12-04 |  |  |
| AstraZeneca | Acalabrutinib | Calquence |  | 2020-11-05 | $1,631 M | Q1/21-Q2/23 |
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
60%129/216
Phase 2
27%50/188
Phase 3
57%40/70
Approved: 20Overall Success rate: 9%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use